An high level of EGFR amplification was identified in 5/10 (50%) of patients with an AA IDH-wt, thereby allowing the designation of a ‘Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV’ according to cIMPACT-NOW update 3 [25]. This evidence concerns the gene EGFR and glioblastoma.